Penile Implants: Types, Surgery, Recovery, and How They Compare to ED Pills

What Is a Penile Implant?

A penile implant, also called a penile prosthesis, is a surgically implanted device placed inside the corpora cavernosa to produce an erection on demand. The American Urological Association (AUA) guideline on erectile dysfunction lists penile prostheses as the standard surgical option for men with organic ED who have not responded adequately to first-line and second-line therapies. The procedure does not affect orgasm or ejaculation in most cases, and it does not alter penile sensation because the surgery does not disturb penile nerves. Approximately 25,000 to 30,000 implants are placed annually in the United States.

Two broad categories exist. Inflatable devices use a fluid reservoir and pump to mimic a natural erection, while malleable (semi-rigid) rods hold the penis in a bendable but always firm state. The right choice depends on the patient's dexterity, anatomy, prior pelvic surgery, and personal preference. Both types are placed through a small penoscrotal or infrapubic incision.

Candidates are typically men with Peyronie's disease, post-radical prostatectomy ED, diabetic vascular ED, or ED from spinal cord injury. Research published in the Journal of Urology confirms that men with prior prostatectomy represent the largest single referral group for penile prosthesis surgery.

Types of Penile Implants

Three-Piece Inflatable Penile Prosthesis

The three-piece inflatable prosthesis is the most commonly implanted device in the United States. It consists of two intracorporal cylinders, a scrotal pump, and an abdominal fluid reservoir. Squeezing the pump transfers saline from the reservoir into the cylinders, producing an erection. Pressing a deflation valve returns the fluid, creating flaccidity. Patients report natural-looking results and high concealment.

The two dominant systems are the AMS 700 (Boston Scientific) and the Coloplast Titan. A large registry study of 2,034 patients found five-year mechanical reliability rates of 81.4% for the AMS 700 and 79.4% for the Titan, with surgical revisions more common in diabetic patients. Ten-year device survival for current-generation prostheses approaches 85% when infection is prevented.

Two-Piece Inflatable Penile Prosthesis

The two-piece system eliminates the abdominal reservoir, instead combining the reservoir with the scrotal pump. This design suits men who have had prior pelvic surgery, cystectomy, or kidney transplants where reservoir placement would be unsafe. Rigidity and flaccidity are slightly less complete than in three-piece models.

Malleable (Semi-Rigid) Penile Prosthesis

Malleable implants are paired silicone rods placed in the corpora cavernosa. The penis remains firm at all times but can be bent downward for concealment. These devices suit older men, men with limited hand dexterity, or men in developing-country healthcare settings where component failure is harder to manage. The AMS Spectra and Coloplast Genesis are current examples. Satisfaction rates are somewhat lower than inflatable devices, averaging around 70-80%, but mechanical failure is rare given the absence of hydraulic components.

Who Is a Candidate for a Penile Implant?

Penile implant surgery is considered a third-line treatment for ED. First-line treatment is oral PDE5 inhibitors. Second-line options include intraurethral alprostadil (MUSE) and intracavernosal injection therapy. Surgery is appropriate when those approaches fail, are contraindicated, or are unacceptable to the patient.

Specific populations who frequently qualify include:

• Men with post-radical prostatectomy ED who have neuropraxia and do not respond to sildenafil at 100 mg or tadalafil at 20 mg after a supervised penile rehabilitation trial
• Men with severe Peyronie's disease requiring surgical correction of penile curvature
• Men with diabetes-related vasculogenic ED unresponsive to maximum-dose oral therapy
• Men with spinal cord injuries who cannot achieve psychogenic erections
• Men who have failed vacuum erection devices and injection therapy

A 2020 systematic review in Translational Andrology and Urology concluded that patient selection criteria, surgical technique, and antibiotic-coated device technology are the three strongest predictors of long-term success.

The AUA's erectile dysfunction guideline states: "Penile prostheses represent the most effective treatment for erectile dysfunction and provide the highest long-term satisfaction rates when appropriate candidates are selected." That guideline recommends detailed informed consent covering irreversibility, mechanical failure rates, and the possibility that natural erectile tissue is permanently altered.

The Surgical Procedure: What to Expect

Surgery is most commonly performed under spinal or general anesthesia and takes 45 to 90 minutes. Most centers perform it as an outpatient procedure or with a single overnight stay. The surgeon makes one incision (penoscrotal approach is most common) and dilates the corpora cavernosa to fit the cylinders. The reservoir is placed in the space of Retzius or an ectopic pelvic position. A scrotal pump is placed in the most dependent part of the scrotum.

Antibiotic-impregnated device coatings (InhibiZone on AMS 700, Titan with hydrophilic coating) have reduced infection rates from a historic 3-5% to under 1.5% at most high-volume centers. A multicenter study of 2,357 implants found a 1.06% infection rate with antibiotic-coated prostheses versus 2.07% with uncoated devices.

Patients typically wait 4 to 6 weeks before activating the device. Sexual activity can resume at 6 to 8 weeks post-operatively. Pain medication needs are modest and most men discontinue prescription analgesics within one week.

Recovery, Outcomes, and Patient Satisfaction

Recovery timeline matters to most patients considering this procedure. Scrotal swelling resolves in 2 to 4 weeks. Most men return to desk work in 7 to 10 days and physical labor in 4 to 6 weeks.

Satisfaction data are the strongest argument for penile implants in eligible candidates. A study by Montorsi et al. published in European Urology reported 92% patient satisfaction at 48 months for inflatable prostheses. Partner satisfaction in the same cohort reached 96%. These figures exceed those reported for any oral ED medication in comparative trials.

The following framework helps clinicians and patients compare the three main treatment tiers before committing to surgery:

HealthRX ED Treatment Decision Framework

| Treatment Tier | Example Agents | Who It Suits | Approximate Success Rate in Organic ED | |---|---|---|---| | First-line oral | Sildenafil 25-100 mg, Tadalafil 2.5-20 mg, Vardenafil 5-20 mg, Avanafil 50-200 mg | Most men with mild-moderate ED | 60-70% response | | Second-line injectable/intraurethral | Alprostadil ICI, MUSE | Oral therapy failure, post-prostatectomy | 70-80% erection success per use | | Third-line surgical | Three-piece inflatable prosthesis | Oral and injectable failure, Peyronie's, severe vasculogenic ED | 90-95% patient satisfaction at 5 years |

One data point clinicians often cite: satisfaction rates with PDE5 inhibitors in men with post-radical prostatectomy neuropraxic ED drop to 35-40%, making the jump to implant far more defensible in that group than in men with psychogenic or mild vasculogenic ED.

Risks and Complications

No surgery is without risk. For penile implants, the most clinically significant complications are device infection, mechanical failure, and auto-inflation.

Device infection, even at post-coating rates of under 1.5%, is catastrophic if it occurs. It usually requires complete device removal, a washout procedure, and a salvage reimplantation at a minimum of 3 months later. The AUA guideline recommends preoperative MRSA screening and perioperative intravenous antibiotic coverage with an aminoglycoside plus vancomycin as standard practice.

Mechanical failure requiring revision occurs in approximately 15% of inflatable devices at 10 years, most often due to cylinder aneurysm or tubing kink. The AMS 700 CX with MS pump carries a 10-year device survival of roughly 85% based on manufacturer registry data.

Penile length loss after implantation is a widely underreported concern. A study in the Journal of Sexual Medicine found that 70% of men reported subjective penile shortening after implantation, though objective measurements showed a mean loss of only 1.3 cm compared to pre-ED erect length. Counseling on this point before surgery reduces post-operative dissatisfaction significantly.

Other complications include hematoma (1-2%), device migration, and persistent pain, each occurring in less than 3% of cases at experienced centers.

How PDE5 Inhibitors Compare: Sildenafil, Tadalafil, Vardenafil, and Avanafil

Before surgery is ever considered, every candidate should have had an adequate trial of oral PDE5 inhibitors. These four FDA-approved agents all block the PDE5 enzyme in penile smooth muscle, increasing cGMP and sustaining blood flow during sexual stimulation. None of them create an erection independently. Each requires sexual arousal.

Sildenafil (Viagra)

Sildenafil was FDA-approved in 1998 as the first oral ED treatment. Standard dosing is 25 to 100 mg taken 30 to 60 minutes before sex on an empty stomach; a high-fat meal delays absorption by up to 60 minutes and reduces peak plasma concentration. Duration of effect is approximately 4 to 6 hours. A landmark trial of 532 men with organic ED found that 69% achieved improved erections with sildenafil 50 mg versus 22% on placebo. Generic sildenafil is now widely available at a fraction of brand Viagra's price.

Tadalafil (Cialis)

Tadalafil's half-life of 17.5 hours is more than twice that of any other PDE5 inhibitor, enabling a daily 2.5 mg or 5 mg dosing regimen or an as-needed 10 to 20 mg dose. The 36-hour window of potential effect is the longest of the class. Food does not meaningfully affect tadalafil absorption. In the CIALIS Phase III key trial (N=268), 81% of intercourse attempts were successful with tadalafil 20 mg versus 35% with placebo. Daily tadalafil 5 mg also treats lower urinary tract symptoms from benign prostatic hyperplasia simultaneously, a benefit the other agents do not share.

Vardenafil (Levitra, Staxyn)

Vardenafil is chemically similar to sildenafil but shows slightly higher potency in vitro. Approved doses are 5, 10, and 20 mg. Onset is approximately 60 minutes when taken with a standard meal. Staxyn is an orally disintegrating formulation (10 mg) that dissolves on the tongue, useful for men who prefer not to swallow pills or who want more discretion. Duration is 4 to 5 hours. A pooled analysis of 5 Phase III trials (N=2,203) found vardenafil 20 mg produced a 71% success rate for vaginal penetration versus 45% on placebo. Vardenafil has a small QTc-prolonging effect that makes it the least preferred PDE5 inhibitor in men on Class IA or III antiarrhythmics.

Avanafil (Stendra)

Avanafil is the newest FDA-approved PDE5 inhibitor (2012) and has the fastest clinical onset of the class. In studies, meaningful erectile response began as early as 15 minutes after the 200 mg dose. Available doses are 50, 100, and 200 mg. STENDRA Phase III data (N=646) showed a 77% sexual encounter success rate for avanafil 200 mg at 30 minutes versus 48% placebo. Avanafil is more selective for PDE5 over PDE6 (found in retinal photoreceptors), potentially reducing the visual side effects sometimes reported with sildenafil.

PDE5 Inhibitor Comparison at a Glance

| Drug | Onset | Duration | Food Effect | Unique Feature | |---|---|---|---|---| | Sildenafil 25-100 mg | 30-60 min | ~4-6 hr | High-fat meal delays | Lowest cost generic | | Tadalafil 2.5-20 mg | 30-60 min | Up to 36 hr | Minimal | Daily dosing, BPH indication | | Vardenafil 5-20 mg | ~60 min | 4-5 hr | Moderate | ODT (Staxyn) formulation | | Avanafil 50-200 mg | 15-30 min | ~6 hr | Minimal | Fastest onset; better PDE5/PDE6 selectivity |

All four agents are contraindicated with nitrate medications (nitroglycerin, isosorbide mononitrate) due to risk of severe hypotension. Tadalafil's contraindication window with nitrates extends to 48 hours; the others require 24 hours.

When to Move from Oral Therapy to an Implant

Timing matters. Staying on oral therapy too long in men with severe vasculogenic disease or post-prostatectomy ED may allow corporeal smooth muscle fibrosis to progress, reducing implant cylinder capacity. Corpus cavernosum smooth muscle content falls from approximately 40% in normal tissue to under 20% in severely fibrotic ED, a process that makes dilation during implant surgery more difficult.

The AUA erectile dysfunction guideline recommends referring men to a urologist specializing in sexual medicine after two adequate oral therapy trials fail, with "adequate" defined as at least four attempts at maximum tolerated dose with proper timing relative to meals and sexual stimulation.

Men with post-radical prostatectomy ED benefit from early penile rehabilitation (daily low-dose tadalafil 5 mg or vacuum erection device) to preserve oxygenation of erectile tissue. If spontaneous erections have not returned 12 to 18 months after nerve-sparing prostatectomy despite rehabilitation, a prosthesis discussion is appropriate.

Cost and Insurance Coverage

A three-piece inflatable penile implant, including device, surgeon fees, anesthesia, and facility costs, typically runs $15,000 to $25 to 000 in the United States when paid out of pocket. Insurance coverage is common when ED has a documented organic cause (e.g., prostate cancer surgery, diabetes mellitus, spinal cord injury). The ICD-10 code N52.01 (erectile dysfunction due to arterial insufficiency) and N52.34 (post-prostatectomy erectile dysfunction) are the most commonly covered diagnoses.

Medicare covers penile prosthesis implantation under DRG 727 when medical necessity criteria are met. Coverage under private insurance varies by plan; prior authorization is almost always required.

Generic sildenafil can cost as little as $10 to $15 per tablet through GoodRx at major pharmacy chains. Generic tadalafil is comparably priced. Avanafil lacks a generic as of 2025 and runs $60 to $90 per tablet brand-name.